In last trading session, SAB Biotherapeutics Inc (NASDAQ:SABS) saw 88282.0 shares changing hands with its beta currently measuring 0.47. Company’s recent per share price level of $4.03 trading at $0.23 or 6.05% at ring of the bell on the day assigns it a market valuation of $37.19M. That closing price of SABS’s stock is at a discount of -58.56% from its 52-week high price of $6.39 and is indicating a premium of 46.4% from its 52-week low price of $2.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 54320.0 shares which gives us an average trading volume of 98.95K if we extend that period to 3-months.
For SAB Biotherapeutics Inc (SABS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
SAB Biotherapeutics Inc (NASDAQ:SABS) trade information
Upright in the green during last session for gaining 6.05%, in the last five days SABS remained trading in the green while hitting it’s week-highest on Wednesday, 01/08/25 when the stock touched $4.03 price level, adding 7.36% to its value on the day. SAB Biotherapeutics Inc’s shares saw a change of 6.21% in year-to-date performance and have moved 6.21% in past 5-day. SAB Biotherapeutics Inc (NASDAQ:SABS) showed a performance of 31.27% in past 30-days. Number of shares sold short was 56417.0 shares which calculate 0.62 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 32.83% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would jump 25.56% in reaching the projected high whereas dropping to the targeted low would mean a gain of 25.56% for stock’s current value.
SAB Biotherapeutics Inc (SABS) estimates and forecasts
Statistics highlight that SAB Biotherapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 25.94% of value to its shares in past 6 months, showing an annual growth rate of 51.70% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
SAB Biotherapeutics Inc (NASDAQ:SABS)’s Major holders
Insiders are in possession of 19.15% of company’s total shares while institution are holding 34.25 percent of that, with stock having share float percentage of 42.36%. Investors also watch the number of corporate investors in a company very closely, which is 34.25% institutions for SAB Biotherapeutics Inc that are currently holding shares of the company.
